Patient characteristics, transplantation completion, and response (n = 231)
| Parameter . | % . |
|---|---|
| Age at least 60 y | 24 |
| CRP level above 4.0 mg/L | 47 |
| LDH level at least 190 U/L | 21 |
| B2M level above 345 nM | 30 |
| Creatinine level above 176.8 μM | 10 |
| Hemoglobin level below 100 g/L | 35 |
| Albumin level at least 35 g/L | 2 |
| Durie-Salmon stage III | 53 |
| IgA isotype | 18 |
| Plasmacytosis BM biopsy at least 50% | 48 |
| Completed HDT-1 | 85 |
| Completed HDT-2 | 72 |
| Cumulative TRM | 9 |
| Post-HDT2 CR (intent to treat) | 38 |
| Parameter . | % . |
|---|---|
| Age at least 60 y | 24 |
| CRP level above 4.0 mg/L | 47 |
| LDH level at least 190 U/L | 21 |
| B2M level above 345 nM | 30 |
| Creatinine level above 176.8 μM | 10 |
| Hemoglobin level below 100 g/L | 35 |
| Albumin level at least 35 g/L | 2 |
| Durie-Salmon stage III | 53 |
| IgA isotype | 18 |
| Plasmacytosis BM biopsy at least 50% | 48 |
| Completed HDT-1 | 85 |
| Completed HDT-2 | 72 |
| Cumulative TRM | 9 |
| Post-HDT2 CR (intent to treat) | 38 |
The median follow-up was 105 months. As part of follow-up evaluations, aliquots of bone marrow aspirates were routinely submitted for cytogenetic analysis, which was performed on unstimulated Giemsa-banded chromosomes.12 CRP indicates C-reactive protein; LDH, lactate dehydrogenase; B2M, β2microglobulin; Ig, immunoglobulin; BM, bone marrow; HDT, high-dosage transplantation; TRM, transplantation-related mortality; CR, complete remission.